RIPK1 Kinase Assay Kit

Catalog #
79560
$525 *
Size: 96 Reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The RIPK1 Kinase Assay Kit is designed to measure RIPK1 kinase activity for screening and profiling applications using ADP-Glo® Kinase Assay as a detection reagent.
MBP (Myelin Basic Protein) is a non-specific protein substrate that is used as a "universal substrate" for many in-vitro kinase activity assays.  This protein is targeted by many serine/threonine kinases at conserved amino acids. We use the dephosphorylated version of the MBP substrate in our assays to determine the kinase-mediated phosphorylation of MBP.  Our assays are not suitable for studying autophosphorylation of the kinase due to the presence of the MBP substrate.

Synonyms
RCK, MAP3K19, receptor-interacting serine/threonine-protein kinase 1 isoform 1, receptor-interacting serine/threonine-protein kinase 1, serine/threonine-protein kinase RIP, cell death protein RIP, receptor-interacting protein 1, receptor (TNFRSF)-interact
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Supplied As
The RIPK1 Kinase Assay Kit comes in a convenient 96-well format, with enough purified recombinant RIPK1 enzyme, RIPK1 substrate, ATP and kinase assay buffer for 100 enzyme reactions.
Materials Required But Not Supplied

ADP-Glo® Kinase Assay (Promega #V6930)

Dithiothreitol (DTT, 1 M; optional)

Microplate reader capable of reading luminescence

Adjustable micropipettor and sterile tips

30°C incubator

Format
Catalog # Component Amount Storage
40371 RIPK1 10 µg -80°C  Avoid multiple freeze/ thaw cycles!
79334 5x Kinase assay buffer 1.5 ml -20°C 
79686 ATP (500 µM)  100 µl  -20°C 
78514 MBP (5 mg/ml)  100 µl  -20°C 
79696 96-well plate, white 1 Room Temp  

 

UniProt #
Q13546
Background
RIPK1 is a member of the receptor-interacting protein kinase (RIP) family. It plays an important role in cell survival as well as cell death including apoptosis and necroptosis. RIPK1 is highly expressed in Alzheimer’s disease (AD) brains. Importantly, it was shown that inhibition of RIPK1 results in decrease of amyloid and inflammation levels as well as accelerating amyloid beta peptide (Aβ) degradation by microglia in vitro.
References
Ofengeim D., Proc. Natl. Acad. Sci. USA 114(41): E8788-E8797 (2017)